Digital Health Global

MARCH 1, 2023

“We are witnessing unprecedented innovation across the healthcare landscape,” said Robert Mittendorff, MD, General Partner and Head of Healthcare at B Capital. In January 2023, B Capital announced the close of Growth Fund III and affiliated funds with aggregate capital commitments of approximately $2.1 billion.

Healthcare Innovation 88

Healthcare Innovation BioTech Digital Health 88

Digital Health Hub

DECEMBER 6, 2022

Is your 2023 calendar filling up? Here are some digital health events scheduled for 2023. Click on the links to visit the event homepage and also to access the schedule. Last Update : Dec 6,2022. If you are a digital health event organizer, and want to feature your event here, please contact here.

Digital Health 40

Digital Health Healthcare IT BioTech Healthcare Innovation 40

Digital Health Hub

DECEMBER 6, 2022

Is your 2023 calendar filling up? Here are some digital health events scheduled for 2023. Click on the links to visit the event homepage and also to access the schedule.

Digital Health 40

Digital Health Healthcare IT BioTech Healthcare Innovation 40

Digital Health Global

APRIL 17, 2024

Pathology Watch : An end-to-end dermatopathology software platform, including AI interpretation; acquired by Sonic Healthcare in January 2024 for $150 million. Debut Biotech : A leading cell-free biomanufacturing company that launched its own skin care product line in 2023 and raised a $20 million Series B led by L’Oreal.

Life Science 88

Life Science BioTech Healthcare Innovation Digital Health 88

Digital Health Global

FEBRUARY 7, 2023

ABOUT THIRD CULTURE CAPITAL Third Culture Capital (3CC) is an immigrant-founded, physician-led, seed-stage venture capital firm whose mission is to advance equity and diversity in healthcare innovation. Ciba Health was recently named among NY Digital Health 100 winners for 2023. 3CC Founder and Managing Partner Julien L.

Chronic pain management 88

Chronic pain management BioTech Pain management Healthcare Innovation 88

Digital Health Global

MAY 8, 2023

The transaction is expected to close in the second half of 2023, subject to receipt of customary regulatory approvals and satisfaction of other customary closing conditions. For the full fourth quarter 2023, Baxter estimates the transaction to result in dilution of approximately $0.10 Advent International Inc.

Pharmaceuticals 88

Pharmaceuticals Life Science BioTech Leadership 88

Digital Health Today

NOVEMBER 28, 2023

This has created opportunities for other organizations and events to lure the attendees and interest of healthcare innovators and executives. Despite the significant costs, poor weather, and the time spent in transit, the JPM Conference remains an undeniable force for the healthcare and life sciences industry.

Life Science 52

Life Science BioTech Pharmaceuticals Healthcare Innovation 52